[1] Befroy DE, Falk Petersen K, Rothman DL, et al. Assessment of in vivo mitochondrial metabolism by magnetic resonance spec troscopy. Methods Enzymol, 2009, 457: 373-393.
[2] Conley KE, Amara CE, Jubrias SA, et al. Mitochondrial function, fibre types and ageing: new insights from human muscle in vivo. Exp Physiol, 2007, 92(2): 333-339.  doi: 10.1113/expphysiol.2006.034330
[3] van den Broek NM, Ciapaite J, De Feyter HM, et al. Increased mitochondrial content rescues in vivo muscle oxidative capacity in long-term high-fat-diet-fed rats. FASEB J, 2010, 24(5): 1354-1364.  doi: 10.1096/fj.09-143842
[4] van den Broek NM, Ciapaite J, Nicolay K, et al. Comparison of in vivo postexercise phosphocreatine recovery and resting ATP synthesis flux for the assessment of skeletal muscle mitochondrial function. Am J Physiol Cell Physiol, 2010, 299(5): C1136-C1143.  doi: 10.1152/ajpcell.00200.2010
[5] Fleischman A, Johnsen S, Systrom DM, et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab, 2007, 292(6): E1666-E1673.  doi: 10.1152/ajpendo.00550.2006
[6] Forester BP, Berlow YA, Harper DG, et al. Age-related changes in brain energetics and phospholipid metabolism. NMR Biomed, 2010, 23(3): 242-250.  doi: 10.1002/nbm.1444
[7] Hadigan C, Liebau J, Andersen R, et al. Magnetic resonance spectroscopy of hepatic lipid content and associated risk factors in HIV infection. J Acquir Immune Defic Syndr, 2007, 46(3): 312-317.  doi: 10.1097/QAI.0b013e3181568cc2
[8] Powers WJ. PET studies of cerebral metabolism in Parkinson disease. J Bioenerg Biomembr, 2009, 41(6): 505-508.  doi: 10.1007/s10863-009-9251-5
[9] Simons AL, Mattson DM, Dornfeld K, et al. Glucose deprivation-induced metabolic oxidative stress and cancer therapy. J Cancer Res Ther, 2009, 5(Suppl 1): S2-S6.
[10] Madar I, Ravert H, Nelkin B, et al. Characterization of membrane potential-dependent uptake of the novel PET tracer 18F-fluorobenzyl triphenylphosphonium cation. Eur J Nucl Med Mol Imaging, 2007, 34(12): 2057-2065.  doi: 10.1007/s00259-007-0500-8
[11] Matsuo S, Nakae I, Tsutamoto T, et al. A novel clinical indicator using Tc-99m sestamibi for evaluating cardiac mitochondrial function in patients with cardiomyopathies. J Nucl Cardiol, 2007, 14(2): 215-220.  doi: 10.1016/j.nuclcard.2006.10.022
[12] Turner C, Schapira AH. Mitochondrial matters of the brain: the role in Huntington's disease. J Bioenerg Biomembr, 2010, 42(3): 193-198.  doi: 10.1007/s10863-010-9290-y
[13] Duro D, Duggan C, Valim C, et al. Novel intravenous (13)C-methionine breath test as a measure of liver function in children with short bowel syndrome. J Pediatr Surg, 2009, 44(1): 236-240.  doi: 10.1016/j.jpedsurg.2008.10.046
[14] Milazzo L, Menzaghi B, Caramma I, et al. Effect of antioxidants on mitochondrial function in HIV-1-related lipoatrophy: a pilot study. AIDS Res Hum Retroviruses, 2010, 26(11): 1207-1214.  doi: 10.1089/aid.2010.0024
[15] Banasch M, Frank J, Serova K, et al. Impact of antiretroviral treatment on (13) C-methionine metabolism as a marker of hepatic mitochondrial function: a longitudinal study. HIV Med, 2011, 12(1): 40-45.  doi: 10.1111/j.1468-1293.2010.00847.x
[16] Martin FM, Xu X, von Löhneysen K, et al. SOD2 deficient erythroid cells up-regulate transferrin receptor and down-regulate mitochondrial biogenesis and metabolism. PLoS One, 2011, 6(2): e16894.  doi: 10.1371/journal.pone.0016894
[17] Haas RH, Parikh S, Falk MJ, et al. The in-depth evaluation of sus pected mitochondrial disease. Mol Genet Metab, 2008, 94(1): 16-37.  doi: 10.1016/j.ymgme.2007.11.018
[18] Hanawa N, Shinohara M, Saberi B, et al. Role of JNK translocation to mitochondria leading to inhibition of mitochondria bioenergetics in acetaminophen-induced liver injury. J Biol Chem, 2008, 283(20): 13565-13577.  doi: 10.1074/jbc.M708916200
[19] Milinkovic A, Martinez E, López S, et al. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther, 2007, 12(3): 407-415.
[20] Chêne G, Amellal B, Pédrono G, et al. Changes in the peripheral blood mtDNA levels in naive patients treated by different nucleoside reverse transcriptase inhibitor combinations and their association with subsequent lipodystrophy. AIDS Res Hum Retroviruses, 2007, 23(1): 54-61.  doi: 10.1089/aid.2006.0039
[21] García-Ramírez M, Francisco G, García-Arumí E, et al. Mitochondrial DNA oxidation and manganese superoxide dismutase activity in peripheral blood mononuclear cells from type 2 diabetic patients. Diabetes Metab, 2008, 34(2): 117-124.  doi: 10.1016/j.diabet.2007.10.011
[22] Sternfeld T, Schmid M, Tischleder A, et al. The influence of HIV infection and antiretroviral therapy on the mitochondrial membrane potential of peripheral mononuclear cells. Antivir Ther, 2007, 12(5): 769-778.